Research Highlight: Study on COVID‑19 in Children With Neuromuscular Disorders
Study from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society
The NMD4C would like to highlight a paper from the Neuromuscular Working Group of the Spanish Pediatric Neurology Society, who have recently published a study which aims to describe the clinical characteristics and outcome of COVID-19 in the pediatric NMD patient population.
The most prevalent NMD in the study were SMA type 1 and 2 (including patients undergoing treatment with nusinersen, risdiplam or salbutamol), and Duchenne Muscular Dystrophy (including patients undergoing treatment with deflazacort), along with several other neuromuscular conditions.
Although derived from a small sample size, the study’s conclusions suggest that the course of COVID-19 in pediatric NMD populations may not be as severe as expected, due to the mitigating role of young age compared to risk factors including decreased respiratory capacity or a weak cough.
The NMD4C hopes to see further studies published which examine the impact of the COVID-19 virus across both adult and pediatric NMD populations to further our knowledge of its impact within our community.
Read the full article here
Read next...
2027 NMD4C–RARE.Qc Basic Science Research Summer School Applications Are Now Open!
Deadline: December 1, 2026
2027 NMD4C–RARE.Qc Basic Science Research Summer School Applications Are Now Open!
The summer school offers neuromuscular and rare disease research trainees the opportunity to participate in an intensive three-day training program focused on cutting-edge experimental and translational research techniques.
